Juan Pablo Ochoa (@jpocardio) profile picture

Cardiologist. Clinical Director of Health in Code; researcher in CNIC and Puerta de Hierro Hospital (Inherited Cardiomyopathies). Owner and creator of Poolsito.

Madrid, Comunidad de Madrid
Joined October 2010
Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)Photo by Juan Pablo Ochoa (@jpocardio)
🚨 Live from #ESCCongress + now online in @CircAHA 🚨 ahajournals.org/eprint/IMVYI… Honored to present our work on Intermediate-Effect Variants (IEVs) in HCM, selected for the Young Investigator Award. 🏆 60% of HCM cases G (-). Maybe we’ve been looking in the wrong place… 👇🧵
3
13
30
2,161
Juan Pablo Ochoa retweeted
As a first-timer at @ISA_Amyloidosis, I was honoured to deliver 4 presentations on ongoing #ATTR projects and to receive the #ISA2026 Presidential Award ✨️ So glad to share this with my fellow-friends and mentors 🥹
1
43
2,026
Juan Pablo Ochoa retweeted
🧵 Happy to present the results of our study on genetic retesting in hypertrophic cardiomyopathy (HCM), published in the European Heart Journal. What can retesting reveal after a negative result? doi.org/10.1093/eurheartj/eh…
1
13
38
1,487
1/ New paper in Circ Genom Precis Med 🧬 Why do two people with the same MYBPC3 variant have such different hypertrophic cardiomyopathy? Part of the answer: what else they carry in their genome. 🧵
3
23
53
2,483
Juan Pablo Ochoa retweeted
Important data on MYBPC related HCM and the genetic architecture of a large cohort of patients including compound heterozygous variants ahajournals.org/doi/10.1161/…
10
33
2,448
Imponente Simposium de Genética Cardiovascular con María Sabater, M. Valverde y J.P Ochoa. "La mejor sesión del congreso" E. Villacorta y ML Peña
5
10
579
Juan Pablo Ochoa retweeted
Great discussion on Genetics in #HCM 🫀🧬 by @jpocardio and @fdefrutossemi. 'Do not mix uncertainty with effect'! The importance of pursuing the genetic cause for #HCM families and reviewing variant classification‼️
3
13
644
Variantes de efecto intermedio en miocardiopatía hipertrófica por el Dr Juan Pablo Ochoa 🧬❤️ @SAC_54 @jpocardio
1
6
151
Juan Pablo Ochoa retweeted
1
1
877
Juan Pablo Ochoa retweeted
En medicina (y en la vida), nos encantan las categorías claras. ✅ Positivo vs. Negativo ❌ ✅ Leve vs. Grave ❌ ✅ Normal vs. Patológico ❌ Pero la realidad rara vez es tan ordenada. Entre los extremos, hay grises que muchas veces pasamos por alto. Porque incomodan, porque no ofrecen certezas inmediatas. 1/6👇
1
2
4
247
Replying to @RevEspCardiol
Gracias @health_in_code por una base de datos que permite análisis así. Y por supuesto al equipo de cardio y resto de autores!! ❤️🙌🏻 @ivonnecardenasr @jpocardio
1
3
106
Resultados preliminares de una nueva terapia génica en MCH por MYBPC3 secardiologia.es/blog/16151-…
5
6
614
.@peiro_belen: "Las variantes de efecto intermedio emergen como un componente clave en la arquitectura genética de la miocardiopatía hipertrófica, aportando nuevos elementos al modelo clásico centrado en las variantes monogénicas". #BlogSEC @jovenesSEC ow.ly/QxZ350XCARB
5
8
1,274